LUKE VERRET: Open Payments
NPI 1851785810 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$656 in 41 payments from 13 companies in 2025. Trend: 2023 $444 · 2024 $669 · 2025 $656
Food & beverage: $656
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 14 | $221 |
| Corium, LLC | 10 | $109 |
| Teva Pharmaceuticals USA, Inc. | 3 | $63 |
| E.R. Squibb & Sons, L.L.C. | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Janssen Pharmaceuticals, Inc | 2 | $31 |
| Neurocrine BioSciences, Inc. | 1 | $26 |
| Tris Pharma Inc | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $22 |
| Indivior Inc. | 1 | $20 |
Products named: Qelbree, Azstarys, COBENFY, AUSTEDO XR, INGREZZA, Dyanavel XR, UZEDY, SUBLOCADE.
Industry payments across LA — which companies pay providers there.
